Skip to content

Study · Animal study (in vivo) · mouse · 2014

7 results

Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis.

Xiang XS, Li N, Zhao YZ, Li QR, Li JS

Inflammation1 Apr 2014Cited by 9 (Europe PMC)

PMID24122349 (opens in a new tab)DOI10.1007/s10753-013-9753-5 (opens in a new tab)PepBankPUB-24122349
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In endotoxemic mice, thymosin alpha‑1 induced significant increases in dendritic cell numbers in vivo.

    In plain wordsIn mice with endotoxemia, thymosin alpha‑1 raised the number of dendritic immune cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseDendritic cell numbers in vivo
    Study

    mousen: not reported in source

    Endotoxemic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tα1 induced significant increases in DC numbers in vivo, whereas DXM reduced cell numbers both in vitro and in vivo.
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    Thymosin alpha‑1 did not significantly change the capacity of dendritic cells to induce T cell activation.

    In plain wordsIn mice with endotoxemia, thymosin alpha‑1 did not change how well dendritic cells activate T cells.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeDendritic cell capacity to induce T cell activation
    Study

    mousen: not reported in source

    Endotoxemic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, neither drug induced significant changes in the capacity of DCs to induce T cell activation or their expression of MHCII or CD86.
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.
  3. 03AnimalAnimal study (in vivo)Mechanism

    Thymosin alpha‑1 did not significantly change MHCII expression on dendritic cells.

    In plain wordsIn mice with endotoxemia, thymosin alpha‑1 did not change MHCII on dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeMHCII expression on dendritic cells
    Study

    mousen: not reported in source

    Endotoxemic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, neither drug induced significant changes in the capacity of DCs to induce T cell activation or their expression of MHCII or CD86.
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.
  4. 04AnimalAnimal study (in vivo)Mechanism

    Thymosin alpha‑1 did not significantly change CD86 expression on dendritic cells.

    In plain wordsIn mice with endotoxemia, thymosin alpha‑1 did not change CD86 on dendritic cells.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCD86 expression on dendritic cells
    Study

    mousen: not reported in source

    Endotoxemic mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, neither drug induced significant changes in the capacity of DCs to induce T cell activation or their expression of MHCII or CD86.
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 05AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In endotoxemic mice, the combination of dexamethasone and thymosin alpha‑1 gave the highest survival rate among five treatment groups.

    In plain wordsIn mice with endotoxemia, dexamethasone plus thymosin alpha‑1 gave the highest survival among five treatments.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival rate with dexamethasone plus Tα1
    Study

    mousen: not reported in source

    Endotoxemic mice
    Comparator
    Other treatment groups
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    Among the five treatment groups, the mice treated with a combination of DXM and Tα1 had the highest survival rate; this increased survival was associated with a decrease in bacterial translocation to extra-intestinal organs and an enhanced ability to eradicate secondary infections by reversing the c…
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 06AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In endotoxemic mice, the dexamethasone and thymosin alpha‑1 combination was associated with decreased bacterial translocation to extra-intestinal organs.

    In plain wordsIn mice with endotoxemia, dexamethasone plus thymosin alpha‑1 was linked to less spread of gut bacteria to other organs.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseBacterial translocation with dexamethasone plus Tα1
    Study

    mousen: not reported in source

    Endotoxemic mice
    Comparator
    Other treatment groups
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Among the five treatment groups, the mice treated with a combination of DXM and Tα1 had the highest survival rate; this increased survival was associated with a decrease in bacterial translocation to extra-intestinal organs and an enhanced ability to eradicate secondary infections by reversing the c…
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 07AnimalNot a test of Thymosin alpha-1 aloneAnimal study (in vivo)Efficacy outcome

    In endotoxemic mice, the dexamethasone and thymosin alpha‑1 combination enhanced the ability to eradicate secondary infections.

    In plain wordsIn mice with endotoxemia, dexamethasone plus thymosin alpha‑1 was linked to better clearing of a second infection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseEradication of secondary infections with dexamethasone plus Tα1
    Study

    mousen: not reported in source

    Endotoxemic mice
    Comparator
    Other treatment groups
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Among the five treatment groups, the mice treated with a combination of DXM and Tα1 had the highest survival rate; this increased survival was associated with a decrease in bacterial translocation to extra-intestinal organs and an enhanced ability to eradicate secondary infections by reversing the c…
    1 context sentence
    Summary · context
    Endotoxemic mice were randomly divided into five treatment groups.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.